Intech Biopharm Corporation (TPEX: 6461)
Taiwan
· Delayed Price · Currency is TWD 29.80
+0.35 (1.19%)
Oct 9, 2024, 1:30 PM CST
Intech Biopharm Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 32.28 | 25.85 | 23.65 | 38.9 | 21.11 | 16.68 | Upgrade
|
| Revenue Growth (YoY) | 58.76% | 9.30% | -39.21% | 84.30% | 26.50% | -3.19% | Upgrade
|
| Cost of Revenue | 193.41 | 189.84 | 170.91 | 158.27 | 160 | 162.71 | Upgrade
|
| Gross Profit | -161.14 | -164 | -147.26 | -119.37 | -138.89 | -146.02 | Upgrade
|
| Selling, General & Admin | 54 | 51.99 | 52.14 | 47.98 | 39.35 | 58.79 | Upgrade
|
| Research & Development | 119.83 | 104.49 | 118.68 | 126.63 | 62.32 | 94.89 | Upgrade
|
| Operating Expenses | 173.83 | 156.47 | 170.82 | 174.61 | 101.67 | 153.68 | Upgrade
|
| Operating Income | -334.97 | -320.47 | -318.08 | -293.98 | -240.56 | -299.71 | Upgrade
|
| Interest Expense | -34.24 | -33.59 | -23.04 | -19.54 | -16.81 | -19.31 | Upgrade
|
| Interest & Investment Income | 6 | 4.42 | 1.93 | 0.85 | 0.72 | 0.33 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.06 | 0.04 | 0.18 | -0.08 | 0.02 | -0.06 | Upgrade
|
| Other Non Operating Income (Expenses) | 11.57 | 11.61 | 11.14 | 11 | 6.26 | 7.32 | Upgrade
|
| EBT Excluding Unusual Items | -351.58 | -337.99 | -327.88 | -301.76 | -250.37 | -311.42 | Upgrade
|
| Pretax Income | -351.58 | -337.99 | -327.88 | -301.76 | -250.37 | -311.42 | Upgrade
|
| Net Income | -351.58 | -337.99 | -327.88 | -301.76 | -250.37 | -311.42 | Upgrade
|
| Net Income to Common | -351.58 | -337.99 | -327.88 | -301.76 | -250.37 | -311.42 | Upgrade
|
| Shares Outstanding (Basic) | 131 | 120 | 116 | 102 | 100 | 82 | Upgrade
|
| Shares Outstanding (Diluted) | 131 | 120 | 116 | 102 | 100 | 82 | Upgrade
|
| Shares Change (YoY) | 12.23% | 3.73% | 14.15% | 1.47% | 22.87% | 5.02% | Upgrade
|
| EPS (Basic) | -2.69 | -2.81 | -2.82 | -2.97 | -2.50 | -3.82 | Upgrade
|
| EPS (Diluted) | -2.69 | -2.81 | -2.82 | -2.97 | -2.50 | -3.82 | Upgrade
|
| Free Cash Flow | -284.78 | -234.17 | -201.13 | -221.91 | -215.54 | -240.39 | Upgrade
|
| Free Cash Flow Per Share | -2.18 | -1.94 | -1.73 | -2.18 | -2.15 | -2.95 | Upgrade
|
| Operating Margin | -1037.75% | -1239.87% | -1345.12% | -755.76% | -1139.78% | -1796.37% | Upgrade
|
| Profit Margin | -1089.22% | -1307.64% | -1386.55% | -775.74% | -1186.25% | -1866.60% | Upgrade
|
| Free Cash Flow Margin | -882.27% | -905.98% | -850.56% | -570.48% | -1021.21% | -1440.87% | Upgrade
|
| EBITDA | -249.83 | -235.74 | -232.8 | -208.82 | -156.68 | -226.43 | Upgrade
|
| D&A For EBITDA | 85.14 | 84.73 | 85.28 | 85.16 | 83.88 | 73.27 | Upgrade
|
| EBIT | -334.97 | -320.47 | -318.08 | -293.98 | -240.56 | -299.71 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.